

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

**POLL RESULTS OF THE 2022 FIRST EXTRAORDINARY
GENERAL MEETING HELD ON 4 JANUARY 2022**

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that, at the 2022 first extraordinary general meeting of the Company (the “**EGM**”) held at 2:30 p.m. on Tuesday, 4 January 2022 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, the proposed resolution set out in the notice of the EGM was passed by way of poll. For details of the resolution considered at the EGM, the Shareholders may refer to the notice of the EGM dated 13 December, 2021 and the circular of the EGM dated 13 December, 2021 of the Company (the “**Circular**”). Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, the total number of Shares in issue is 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). No Shareholder was required to abstain from voting on the resolution under the Listing Rules. There was no Share entitling the holder to attend the meeting and abstain from voting in favor of the resolution under Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolution proposed at the EGM. Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of the H Shares at the EGM. The convening of the EGM was in compliance with the Company Law of the PRC and the Articles of Association.

The following directors of the Company (“**Directors**”): the executive Directors, Mr. Li Li and Mr. Shan Yu; and the independent non-executive Directors, Dr. Lu Chuan and Mr. Chen Junfa attended the EGM.

I. CONVENING OF THE MEETING

The total number of Shares entitling the holders to attend and vote on the resolution at the EGM was 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 1,018,028,765 Shares (including 990,924,649 A Shares and 27,104,116 H Shares), representing approximately 69.3813% of the total number of Shares.

II. POLL RESULTS OF THE EGM

The poll results in respect of the resolution at the EGM are set out below:

SPECIAL RESOLUTION	NUMBER OF VOTES (APPROXIMATE %)		
	FOR	AGAINST	ABSTAIN
To consider and approve the proposed issuance of corporate bonds in the PRC by the Company, and to authorise Mr. Li Li, chairman of the board of directors of the Company, and any person authorised by him to deal with the relevant matters (details of this resolution were set out in the notice of EGM dated 13 December 2021)	1,017,975,265 (99.9947%)	53,500 (0.0053%)	0 (0%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the resolution, the resolution was duly passed as a special resolution.

By Order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
4 January, 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.